

Serial No.: 09/807,657
Group Art Unit No.: 1648

In the Claims:

Claims 1-31 (Cancelled).

32. (Previously Presented) An adjuvant composition comprising an immunostimulant adsorbed onto a metallic salt particle, wherein the metallic salt particle is substantially free of antigen and wherein the immunostimulant is not a saponin derived from the bark of *Quillaja Saponaria* Molina.

33. (Previously Presented) An adjuvant composition as claimed in claim 32, wherein the metallic salt particle is a salt of aluminium, zinc, calcium, cerium, chromium, iron, or berilium.

34. (Previously Presented) An adjuvant composition as claimed in claim 32, wherein the metallic salt is a phosphate or hydroxide.

35. (Previously Presented) An adjuvant composition as claimed in claim 32, wherein the metallic salt is aluminium hydroxide or aluminium phosphate.

36. (Previously Presented) An adjuvant composition as claimed in claim 32, wherein the immunostimulant is monophosphoryl lipid A or a derivative thereof.

37. (Previously Presented) An adjuvant composition as claimed in claim 36, wherein the derivative of monophosphoryl lipid A is 3-de-O-acylated monophosphoryl lipid A.

38. (Cancelled).

39. (Previously Presented) A process for the manufacture of a vaccine composition comprising the admixture of a) an adjuvant composition comprising an immunostimulant adsorbed onto a first metallic salt particle substantially free of antigen, and b) an antigen.

40. (Previously Presented) A process for the manufacture of a vaccine composition as claimed in claim 39, wherein the antigen is adsorbed onto a second metallic salt particle

Serial No.: 09/807,657
Group Art Unit No.: 1648

substantially free of antigen wherein the metallic salt of each of the first metallic salt particle and the second metallic salt particle may be the same.

41. (Currently Amended) A process ~~as claimed in claims 39~~ for the manufacture of an immunogenic composition comprising the admixture of a) an adjuvant composition comprising an immunostimulant adsorbed onto a first metallic salt particle substantially free of antigen, and b) an antigen, wherein the antigen of b) elicits an immune response to a pathogen, polypeptide, or anti-tumour antigen selected from the group comprising: antigens derived from Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex Virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, human papilloma virus, Influenza virus, *Haemophilus influenzae* Type B ("Hib"), Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, IgE peptides, Der p1, pollen related antigens; or Tumor associated antigens (TAA), MAGE, BAGE, GAGE, MUC-1, Her-2 neu, luteinizing hormone-releasing hormone (gonadotropin-releasing hormone) LHRH(GnRH), CEA, PSA, KSA, ~~or~~ and PRAME.

42. (Previously Presented) A vaccine composition comprising an adjuvant composition according to any one of claims 32 to 37, additionally comprising an antigen.

43. (Currently Amended) A vaccine composition produced according to the process claimed in either any one of claims 39 or 40 ~~to 41~~.

44. (Previously Presented) A vaccine comprising a saponin adsorbed onto a metallic salt particle wherein the vaccine comprises an antigen, characterised in that the metallic salt particle is substantially free of said antigen.

45. (Previously Presented) A vaccine according to claim 44, wherein the saponin is QS21.

46. (Previously Presented) A vaccine composition comprising two major populations of complexes, a first complex comprising (a) an immunostimulant adsorbed onto a metallic salt

Serial No.: 09/807,657
Group Art Unit No.: 1648

particle, characterised in that said metallic salt particle is substantially free of antigen; and a second complex comprising (b) antigen adsorbed onto a metallic salt particle.

47. (Previously Presented) A vaccine composition comprising two major populations of complexes, a first complex comprising (a) an immunostimulant adsorbed onto a metallic salt particle, characterised in that said metallic salt particle is substantially free of antigen; and a second complex comprising (b) antigen adsorbed onto a metallic salt particle, characterised in that said metallic salt particle is substantially free of immunostimulant of the first complex.

48. (Previously Presented) A vaccine composition as claimed in claims 46 or 47, wherein the metallic salt present in the first and second complexes are identical.

49. (Previously Presented) A vaccine composition as claimed in claims 46 or 47, wherein the second complex comprises a plurality of sub-complexes, each sub-complex comprising a different antigen adsorbed onto a metallic salt particle.

50. (Previously Presented) A vaccine composition as claimed in any one of claims 44 to 47, wherein the metallic salt is a salt of aluminium, zinc, calcium, cerium, chromium, iron, or berilium.

51. (Previously Presented) A vaccine as claimed in claim 50 wherein the metallic salt is a phosphate or hydroxide.

52. (Previously Presented) A vaccine composition as claimed in claim 51 wherein the metallic salt is aluminium hydroxide or aluminium phosphate.

53. (Previously Presented) A vaccine composition as claimed in claim 42, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

54. (Previously Presented) A vaccine composition as claimed in claim 43, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

55. (Previously Presented) A vaccine composition as claimed in claim 45, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

Serial No.: 09/807,657
Group Art Unit No.: 1648

56. (Previously Presented) A vaccine composition as claimed in claim 46, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

57. (Previously Presented) A vaccine composition as claimed in claim 47, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

58. (Previously Presented) A vaccine composition as claimed in claim 48, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

59. (Previously Presented) A vaccine composition as claimed in claim 49, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

60. (Previously Presented) A vaccine composition as claimed in claim 50, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

61. (Previously Presented) A vaccine composition as claimed in claim 51, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

62. (Previously Presented) A vaccine composition as claimed in claim 52, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

Claims 63-70. (Cancelled).

71. (Currently Amended) ~~An immunogenic vaccine~~ composition as claimed in claim ~~127~~ 42, wherein the antigen elicits an immune response against a pathogen, polypeptide, or anti-tumour antigen selected from the group consisting of: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, *Haemophilus influenzae* Type B ("Hib"), Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, luteinizing hormone-releasing hormone (gonadotropin-releasing hormone)(~~LHRH~~(~~GnRH~~), CEA, PSA, tyrosinase, Survivin, KSA, ~~and~~ PRAME, RTS,S, P.

Serial No.: 09/807,657
Group Art Unit No.: 1648

P. faciparum MSP1, *P. faciparum* AMA1, *P. faciparum* MSP3, *P. faciparum* EBA, *P. faciparum* GLURP, *P. faciparum* RAP1, *P. faciparum* RAP2, *P. faciparum* Sequestrin, *P. faciparum* PfEMP1, *P. faciparum* Pf332, *P. faciparum* LSA1, *P. faciparum* LSA3, *P. faciparum* STARP, *P. faciparum* SALSA, *P. faciparum* PfEXPa, *P. faciparum* Pfs25, *P. faciparum* Pfs28, *P. faciparum* PFS27/25, *P. faciparum* Pfs16, *P. faciparum* Pfs48/45, *P. faciparum* Pfs230, and any analogues of *P. faciparum* antigens from *Plasmodium* ssp.

72. (Currently Amended) An immunogenic vaccine composition as claimed in claim 128 43, wherein the antigen elicits an immune response against a pathogen, polypeptide, or anti-tumour antigen selected from the group consisting of: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, *Haemophilus influenzae* Type B ("Hib"), Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, luteinizing hormone-releasing hormone (gonadotropin-releasing hormone)(LHRH(GnRH)), CEA, PSA, tyrosinase, Survivin, KSA, and PRAME, RTS,S, *P. faciparum* MSP1, *P. faciparum* AMA1, *P. faciparum* MSP3, *P. faciparum* EBA, *P. faciparum* GLURP, *P. faciparum* RAP1, *P. faciparum* RAP2, *P. faciparum* Sequestrin, *P. faciparum* PfEMP1, *P. faciparum* Pf332, *P. faciparum* LSA1, *P. faciparum* LSA3, *P. faciparum* STARP, *P. faciparum* SALSA, *P. faciparum* PfEXPa, *P. faciparum* Pfs25, *P. faciparum* Pfs28, *P. faciparum* PFS27/25, *P. faciparum* Pfs16, *P. faciparum* Pfs48/45, *P. faciparum* Pfs230, and any analogues of *P. faciparum* antigens from *Plasmodium* ssp.

73. (Currently Amended) An immunogenic vaccine composition as claimed in claim 129 44, wherein the antigen elicits an immune response against a pathogen, polypeptide, or anti-tumour antigen selected from the group consisting of: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus,

Serial No.: 09/807,657
Group Art Unit No.: 1648

Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, *Haemophilus influenzae* Type B ("Hib"), Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, luteinizing hormone-releasing hormone (gonadotropin-releasing hormone)(LHRH(GnRH)), CEA, PSA, tyrosinase, Survivin, KSA, ~~and PRAME~~, RTS,S, P. faciparum MSP1, P. faciparum AMA1, P. faciparum MSP3, P. faciparum EBA, P. faciparum GLURP, P. faciparum RAP1, P. faciparum RAP2, P. faciparum Sequestrin, P. faciparum PfEMP1, P. faciparum Pf332, P. faciparum LSA1, P. faciparum LSA3, P. faciparum STARP, P. faciparum SALSA, P. faciparum PfEXPa, P. faciparum Pfs25, P. faciparum Pfs28, P. faciparum PFS27/25, P. faciparum Pfs16, P. faciparum Pfs48/45, P. faciparum Pfs230, and any analogues of P. faciparum antigens from Plasmodium spp.

74. (Currently Amended) An immunogenic vaccine composition as claimed in claim 130 45, wherein the antigen elicits an immune response against a pathogen, polypeptide, or anti-tumour antigen selected from the group consisting of: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, *Haemophilus influenzae* Type B ("Hib"), Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, luteinizing hormone-releasing hormone (gonadotropin-releasing hormone)(LHRH(GnRH)), CEA, PSA, tyrosinase, Survivin, KSA, ~~and PRAME~~, RTS,S, P. faciparum MSP1, P. faciparum AMA1, P. faciparum MSP3, P. faciparum EBA, P. faciparum GLURP, P. faciparum RAP1, P. faciparum RAP2, P. faciparum Sequestrin, P. faciparum PfEMP1, P. faciparum Pf332, P. faciparum LSA1, P. faciparum LSA3, P. faciparum STARP, P. faciparum SALSA, P. faciparum PfEXPa, P. faciparum Pfs25, P. faciparum Pfs28, P. faciparum

Serial No.: 09/807,657
Group Art Unit No.: 1648

PFS27/25, *P. faciparum* Pfs16, *P. faciparum* Pfs48/45, *P. faciparum* Pfs230, and any analogues of *P. faciparum* antigens from *Plasmodium* ssp.

75. (Currently Amended) An immunogenic vaccine composition as claimed in claim 131 46, wherein the antigen elicits an immune response against a pathogen, polypeptide, or anti-tumour antigen selected from the group consisting of: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, *Haemophilus influenzae* Type B ("Hib"), Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, luteinizing hormone-releasing hormone (gonadotropin-releasing hormone)(LHRH(GnRH)), CEA, PSA, tyrosinase, Survivin, KSA, ~~and~~ PRAME, RTS,S, *P. faciparum* MSP1, *P. faciparum* AMA1, *P. faciparum* MSP3, *P. faciparum* EBA, *P. faciparum* GLURP, *P. faciparum* RAP1, *P. faciparum* RAP2, *P. faciparum* Sequestrin, *P. faciparum* PfEMP1, *P. faciparum* Pf332, *P. faciparum* LSA1, *P. faciparum* LSA3, *P. faciparum* STARP, *P. faciparum* SALSA, *P. faciparum* PfEXPa, *P. faciparum* Pfs25, *P. faciparum* Pfs28, *P. faciparum* PFS27/25, *P. faciparum* Pfs16, *P. faciparum* Pfs48/45, *P. faciparum* Pfs230, and any analogues of *P. faciparum* antigens from *Plasmodium* ssp.

76. (Currently Amended) An immunogenic vaccine composition as claimed in claim 132 47, wherein the antigen elicits an immune response against a pathogen, polypeptide, or anti-tumour antigen selected from the group consisting of: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, *Haemophilus influenzae* Type B ("Hib"), Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1,

Serial No.: 09/807,657

Group Art Unit No.: 1648

Her-2 neu, luteinizing hormone-releasing hormone (gonadotropin-releasing hormone)(LHRH(GnRH)), CEA, PSA, tyrosinase, Survivin, KSA, ~~and~~ PRAME, RTS,S, P. faciparum MSP1, P. faciparum AMA1, P. faciparum MSP3, P. faciparum EBA, P. faciparum GLURP, P. faciparum RAP1, P. faciparum RAP2, P. faciparum Sequesterin, P. faciparum PfEMP1, P. faciparum Pf332, P. faciparum LSA1, P. faciparum LSA3, P. faciparum STARP, P. faciparum SALSA, P. faciparum PfEXPa, P. faciparum Pfs25, P. faciparum Pfs28, P. faciparum PFS27/25, P. faciparum Pfs16, P. faciparum Pfs48/45, P. faciparum Pfs230, and any analogues of P. faciparum antigens from Plasmodium ssp.

77. (Currently Amended) An immunogenic vaccine composition as claimed in claim 133 48, wherein the antigen elicits an immune response against a pathogen, polypeptide, or anti-tumour antigen selected from the group consisting of: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, *Haemophilus influenzae* Type B ("Hib"), Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, luteinizing hormone-releasing hormone (gonadotropin-releasing hormone)(LHRH(GnRH)), CEA, PSA, tyrosinase, Survivin, KSA, ~~and~~ PRAME, RTS,S, P. faciparum MSP1, P. faciparum AMA1, P. faciparum MSP3, P. faciparum EBA, P. faciparum GLURP, P. faciparum RAP1, P. faciparum RAP2, P. faciparum Sequesterin, P. faciparum PfEMP1, P. faciparum Pf332, P. faciparum LSA1, P. faciparum LSA3, P. faciparum STARP, P. faciparum SALSA, P. faciparum PfEXPa, P. faciparum Pfs25, P. faciparum Pfs28, P. faciparum PFS27/25, P. faciparum Pfs16, P. faciparum Pfs48/45, P. faciparum Pfs230, and any analogues of P. faciparum antigens from Plasmodium ssp.

78. (Currently Amended) An immunogenic vaccine composition as claimed in claim 134 49, wherein the antigen elicits an immune response against a pathogen, polypeptide, or anti-tumour

Serial No.: 09/807,657

Group Art Unit No.: 1648

antigen selected from the group consisting of: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, *Haemophilus influenzae* Type B ("Hib"), Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, luteinizing hormone-releasing hormone (gonadotropin-releasing hormone)(LHRH(GnRH)), CEA, PSA, tyrosinase, Survivin, KSA, ~~and~~ PRAME, RTS,S, *P. faciparum* MSP1, *P. faciparum* AMA1, *P. faciparum* MSP3, *P. faciparum* EBA, *P. faciparum* GLURP, *P. faciparum* RAP1, *P. faciparum* RAP2, *P. faciparum* Sequestrin, *P. faciparum* PfEMP1, *P. faciparum* Pf332, *P. faciparum* LSA1, *P. faciparum* LSA3, *P. faciparum* STARP, *P. faciparum* SALSA, *P. faciparum* PfEXPa, *P. faciparum* Pfs25, *P. faciparum* Pfs28, *P. faciparum* PFS27/25, *P. faciparum* Pfs16, *P. faciparum* Pfs48/45, *P. faciparum* Pfs230, and any analogues of *P. faciparum* antigens from *Plasmodium* ssp.

79. (Currently Amended) An immunogenic vaccine composition as claimed in claim ~~135~~ 50, wherein the antigen elicits an immune response against a pathogen, polypeptide, or anti-tumour antigen selected from the group consisting of: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, *Haemophilus influenzae* Type B ("Hib"), Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, luteinizing hormone-releasing hormone (gonadotropin-releasing hormone)(LHRH(GnRH)), CEA, PSA, tyrosinase, Survivin, KSA, ~~and~~ PRAME, RTS,S, *P. faciparum* MSP1, *P. faciparum* AMA1, *P. faciparum* MSP3, *P. faciparum* EBA, *P. faciparum* GLURP, *P. faciparum* RAP1, *P. faciparum* RAP2, *P. faciparum* Sequestrin, *P. faciparum* PfEMP1, *P. faciparum* Pf332, *P. faciparum* LSA1, *P. faciparum* LSA3, *P. faciparum* STARP, *P.*

Serial No.: 09/807,657
Group Art Unit No.: 1648

faciparum SALSA, *P. faciparum* PfEXPa, *P. faciparum* Pfs25, *P. faciparum* Pfs28, *P. faciparum* PFS27/25, *P. faciparum* Pfs16, *P. faciparum* Pfs48/45, *P. faciparum* Pfs230, and any analogues of *P. faciparum* antigens from *Plasmodium* ssp.

80. (Currently Amended) An immunogenic ~~vaccine~~ composition as claimed in claim ~~136~~ 51, wherein the antigen elicits an immune response against a pathogen, polypeptide, or anti-tumour antigen selected from the group consisting of: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, *Haemophilus influenzae* Type B ("Hib"), Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, luteinizing hormone-releasing hormone (gonadotropin-releasing hormone)(LHRH(GnRH)), CEA, PSA, tyrosinase, Survivin, KSA, ~~and~~ PRAME, RTS,S, *P. faciparum* MSP1, *P. faciparum* AMA1, *P. faciparum* MSP3, *P. faciparum* EBA, *P. faciparum* GLURP, *P. faciparum* RAP1, *P. faciparum* RAP2, *P. faciparum* Sequestrin, *P. faciparum* PfEMP1, *P. faciparum* Pf332, *P. faciparum* LSA1, *P. faciparum* LSA3, *P. faciparum* STARP, *P. faciparum* SALSA, *P. faciparum* PfEXPa, *P. faciparum* Pfs25, *P. faciparum* Pfs28, *P. faciparum* PFS27/25, *P. faciparum* Pfs16, *P. faciparum* Pfs48/45, *P. faciparum* Pfs230, and any analogues of *P. faciparum* antigens from *Plasmodium* ssp.

81. (Currently Amended) An immunogenic ~~vaccine~~ composition as claimed in claim ~~137~~ 52, wherein the antigen elicits an immune response against a pathogen, polypeptide, or anti-tumour antigen selected from the group consisting of: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, *Haemophilus influenzae* Type B ("Hib"), Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide,

Serial No.: 09/807,657
Group Art Unit No.: 1648

Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, luteinizing hormone-releasing hormone (gonadotropin-releasing hormone)(LHRH(GnRH)), CEA, PSA, tyrosinase, Survivin, KSA, ~~and~~ PRAME, RTS,S, P. faciparum MSP1, P. faciparum AMA1, P. faciparum MSP3, P. faciparum EBA, P. faciparum GLURP, P. faciparum RAP1, P. faciparum RAP2, P. faciparum Sequesterin, P. faciparum PfEMP1, P. faciparum Pf332, P. faciparum LSA1, P. faciparum LSA3, P. faciparum STARP, P. faciparum SALSA, P. faciparum PfEXPa, P. faciparum Pfs25, P. faciparum Pfs28, P. faciparum PFS27/25, P. faciparum Pfs16, P. faciparum Pfs48/45, P. faciparum Pfs230, and any analogues of P. faciparum antigens from Plasmodium ssp.

82. (Currently Amended) A vaccine composition as claimed in claim ~~42~~ 71, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

83. (Currently Amended) A vaccine composition as claimed in claim ~~43~~ 72, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

84. (Currently Amended) A vaccine composition as claimed in claim ~~44~~ 73, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

85. (Currently Amended) A vaccine composition as claimed in claim ~~45~~ 74, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

86. (Currently Amended) A vaccine composition as claimed in claim ~~46~~ 75, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

87. (Currently Amended) A vaccine composition as claimed in claim ~~47~~ 76, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

Serial No.: 09/807,657
Group Art Unit No.: 1648

88. (Currently Amended) A vaccine composition as claimed in claim 48 ~~77~~, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

89. (Currently Amended) A vaccine composition as claimed in claim 49 ~~78~~, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

90. (Currently Amended) A vaccine composition as claimed in claim 50 ~~79~~, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

91. (Currently Amended) A vaccine composition as claimed in claim 51 ~~80~~, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

92. (Currently Amended) A vaccine composition as claimed in claim 52 ~~81~~, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

93. (Currently Amended) A vaccine composition as claimed in claim 42 ~~71~~, wherein the ~~plasmodium~~-antigen is ~~one or more antigens selected from the following group:~~ RTS,S and ~~TRAP~~.

94. (Currently Amended) A vaccine composition as claimed in claim 43 ~~72~~, wherein the ~~plasmodium~~-antigen is ~~one or more antigens selected from the following group:~~ RTS,S and ~~TRAP~~.

95. (Currently Amended) A vaccine composition as claimed in claim 44 ~~73~~, wherein the ~~plasmodium~~-antigen is ~~one or more antigens selected from the following group:~~ RTS,S and ~~TRAP~~.

Serial No.: 09/807,657
Group Art Unit No.: 1648

96. (Currently Amended) A vaccine composition as claimed in claim 45 ~~74~~, wherein the ~~plasmodium~~-antigen is ~~one or more antigens selected from the following group~~: RTS,S and TRAP.

97. (Currently Amended) A vaccine composition as claimed in claim 46 ~~75~~ wherein the ~~plasmodium~~-antigen is ~~one or more antigens selected from the following group~~: RTS,S and TRAP.

98. (Currently Amended) A vaccine composition as claimed in claim 47 ~~76~~ wherein the ~~plasmodium~~-antigen is ~~one or more antigens selected from the following group~~: RTS,S and TRAP.

99. (Currently Amended) A vaccine composition as claimed in claim 48 ~~77~~ wherein the ~~plasmodium~~-antigen is ~~one or more antigens selected from the following group~~: RTS,S and TRAP.

100. (Currently Amended) A vaccine composition as claimed in claim 49 ~~78~~ wherein the ~~plasmodium~~-antigen is ~~one or more antigens selected from the following group~~: RTS,S and TRAP.

101. (Currently Amended) A vaccine composition as claimed in claim 50 ~~79~~ wherein the ~~plasmodium~~-antigen is ~~one or more antigens selected from the following group~~: RTS,S and TRAP.

102. (Currently Amended) A vaccine composition as claimed in claim 51 ~~80~~ wherein the ~~plasmodium~~-antigen is ~~one or more antigens selected from the following group~~: RTS,S and TRAP.

Serial No.: 09/807,657
Group Art Unit No.: 1648

103. (Currently Amended) A vaccine composition as claimed in claim 52 ~~84~~ wherein the ~~plasmodium-antigen is one or more antigens selected from the following group:~~ RTS,S and TRAP.

104. (Currently Amended) A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to 42 ~~74~~.

105. (Currently Amended) A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to 43 ~~72~~.

106. (Currently Amended) A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to 44 ~~73~~.

107. (Currently Amended) A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to 45 ~~74~~.

108. (Currently Amended) A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to 46 ~~75~~.

109. (Currently Amended) A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to 47 ~~76~~.

Serial No.: 09/807,657
Group Art Unit No.: 1648

110. (Currently Amended) A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to 48 ~~77~~.

111. (Currently Amended) A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to 49 ~~78~~.

112. (Currently Amended) A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to 50 ~~79~~.

113. (Currently Amended) A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to 51 ~~80~~.

114. (Currently Amended) A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to 52 ~~81~~.

115. (Previously Presented) A kit comprising two containers, one container having monophosphoryl lipid A, or derivative thereof, adsorbed onto a metallic salt; and the second container having antigen adsorbed onto a metallic salt.

116. (Previously Presented) An vaccine composition comprising: a) an immunostimulant adsorbed onto a metallic salt particle, wherein the immunostimulant is selected from the group consisting of bacterially derived compounds, monophosphoryl lipid A, immunostimulatory oligonucleotides, CpG, block copolymers, cholera toxin, immunostimulatory cytokines, GM-

Serial No.: 09/807,657
Group Art Unit No.: 1648

CSF, IL-1, polyriboA, polyriboU, and Muramyl tripeptide, and b) an antigen, wherein the antigen is not adsorbed onto the metallic salt particle.

117. (Cancelled).

118. (Previously Presented) An adjuvant composition comprising an immunostimulant adsorbed onto a metallic salt particle, wherein the metallic salt particle is substantially free of antigen and in that the immunostimulant is not a saponin derived from the bark of Quillaja Saponaria Molina.

119. (Previously Presented) A process for the manufacture of a vaccine composition comprising the admixture of a) an adjuvant composition comprising an immunostimulant adsorbed onto a metallic salt particle substantially free of antigen, and b) an antigen.

120. (Previously Presented) A process as claimed in claim 41, wherein the antigen elicits an immune response to human papilloma virus (HPV).

121. (Previously Presented) The process according to claim 120, wherein the HPV is selected from the group of: HPV 6, 11, 16 and 18.

122. (Previously Presented) The process according to claim 120, wherein the antigen is an L1 particle or capsomer.

123. (Previously Presented) A vaccine composition accordingly to claim 42 wherein the antigen elicits an immune response to human papilloma virus (HPV).

124. (Previously Presented) The vaccine composition according to claim 123, wherein the HPV is selected from the group of: HPV 6, 11, 16 and 18.

125. (Previously Presented) A vaccine composition according to claim 123, wherein the antigen is an L1 particle or capsomer.

Serial No.: 09/807,657
Group Art Unit No.: 1648

126. (New) An immunogenic composition produced according to the process claimed in claim 41.

127. (New) An immunogenic composition comprising an adjuvant composition according to any one of claims 32 to 37, additionally comprising an antigen.

128. (New) An immunogenic composition produced according to the process claimed in claim 41.

129. (New) An immunogenic composition comprising a saponin adsorbed onto a metallic salt particle wherein the composition comprises an antigen, characterised in that the metallic salt particle is substantially free of adsorbed antigen.

130. (New) An immunogenic composition according to claim 129, wherein the saponin is QS21.

131. (New) An immunogenic composition comprising two populations of complexes, a first complex comprising a) an immunostimulant adsorbed onto a metallic salt particle, characterised in that said metallic salt particle is substantially free of adsorbed antigen; and a second complex comprising b) antigen adsorbed onto a metallic salt particle.

132. (New) An immunogenic composition comprising two populations of complexes, a first complex comprising a) an immunostimulant adsorbed onto a metallic salt particle, characterised in that said metallic salt particle is substantially free of adsorbed antigen; and a second complex comprising b) antigen adsorbed onto a metallic salt particle, characterised in that said metallic salt particle is substantially free of immunostimulant of the first complex.

Serial No.: 09/807,657
Group Art Unit No.: 1648

133. (New) An immunogenic composition as claimed in claims 131 or 132, wherein the metallic salt present in the first complex is identical to the metallic salt present in the second complex.

134. (New) An immunogenic composition as claimed in claims 131 or 132, wherein the second complex comprises a plurality of sub-complexes, each sub-complex comprising a different antigen adsorbed onto a metallic salt particle.

135. (New) An immunogenic composition as claimed in any one of claims 129 to 132, wherein the metallic salt is a salt of aluminium, zinc, calcium, cerium, chromium, iron, or beryllium.

136. (New) An immunogenic composition as claimed in claim 135 wherein the metallic salt is a phosphate or hydroxide.

137. (New) An immunogenic composition as claimed in claim 136 wherein the metallic salt is aluminium hydroxide or aluminium phosphate.

138. (New) An adjuvant composition comprising an immunostimulant adsorbed onto a metallic salt particle, wherein the metallic salt particle is substantially free of antigen and wherein the immunostimulant is selected from the group consisting of: bacterial derived compound, immunostimulatory oligonucleotide, block copolymer, cholera toxin, and immunostimulatory cytokine.

139. (New) The adjuvant composition of claim 138 wherein the bacterial derived compound is selected from the group consisting of: Monophosphoryl lipid A and 3 De-O-acylated monophosphoryl lipid A.

140. (New) The adjuvant composition of claim 138 wherein the immunostimulatory oligonucleotide is selected from the group consisting of:

Serial No.: 09/807,657
Group Art Unit No.: 1648

CpG,
TCC ATG AGC TTC CTG ACG TT,
TCT CCC AGC GTG CGC CAT, and
TCG TCG TTT TGT CGT TTT GTC GTT.

141. (New) The adjuvant composition of claim 138 wherein the immunostimulatory cytokine is selected from the group consisting of: GM-CSF, IL-1, polyriboA, polyriboU, and Muramyl tripeptide.